Kyoto University

More than 100 million people in the US have this HLA-A haplotype PALO ALTO, Calif., Oct. 29, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are homozygous for HLA A, C, and DPA1. Two clonal lines are available for cell therapy developers and pharmaceutical companies as off-the-shelf products in both GMP and research-grade. I Peace's new iPSC line was generated from a healthy 26-year-old Caucasian male with an A+ blood type. This new line is homozygous for HLA A, C, and DPA1. More than 100 million people (35.91%) in the U.S. have this HLA A haplotype. What it means to cell therapy development When it comes to the transplantation of stem cells and stem cell products, HLA typing is crucial to ensure compatibility between the donor and recipient. Accurate HLA matching increases the likelihood of transplant success and helps minimize immune system rejection of the transplanted stem cells, reducing the risk of potentially life-threatening complications of graft-versus-host disease (GvHD). HLA typing is essential for identifying the most suitable donor and improving patient outcomes in stem cell transplantation. While we believe autologous cell therapy is the ultimate form of iPSC-derived cell therapy, such therapies are still in their infancy, and it is expected to take some more time before they are readily available to people in general. The introduction of HLA homozygous iPSC line is an important development that can help materialize allogenic cell therapy with reduced immune rejection risk to tens of millions of the U.S. population until autologous cell therapies become readily available. It can also make cell therapy available for those with congenital gene disorders. This is a huge step forward to accelerate iPS cell-derived regenerative medicine. I Peace is committed to providing high-quality cell products to its clients by regularly reviewing its processes and traceability procedures and training its staff members to maintain and constantly improve its product quality. I Peace, inc. I Peace, inc. globally develops sales of GMP iPS cells and entrusted manufacturing services of medical grade cells. The company was founded in 2015 by Koji Tanabe, a graduate of Professor Shinya Yamanaka's laboratory at Kyoto University and the second author of the paper that reported the successful establishment of the world's first human iPS cell line. Tanabe has been involved in iPS cell research since the early days of its development and is daily working on innovative technical development to make iPS cells accessible to everyone through I Peace, inc. Our unique technology enables us to produce multiple donor-derived iPS cells in parallel without contamination concerns and to provide a large number of iPS cells at a reasonable price. We support drug discovery and cell medicine development by providing our iPS cell and other cell products as high-quality cell products that meet PMDA and FDA standards to pharmaceutical companies and cell medicine development companies. We are also promoting the production of iPS cells for individuals so that everyone in the world can prepare for the future by possessing his or her own iPS cells. We support pharmaceutical companies and cell medicine development companies so that cell medicine will be within the reach of patients as soon as possible. We aim for the earliest prevalence of regenerative medicine by establishing iPS cell banking services for individuals. I Peace, Inc. Founder & CEO: Koji Tanabe Established: 2015 Headquarters: Palo Alto, California, U.S.A. Subsidiary in Japan: I Peace, Ltd., Kyoto iPS cell manufacturing base: Peace Engine Kyoto, Kyoto Website: SOURCE I Peace, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

KYOTO, Japan, Oct. 7, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. () is excited to announce that the company has successfully developed a funding plan of total 25 billion yen in new Series B funding and raised 22.5 billion yen with the first payment. This significant investment brings the company's total funding to 44 billion yen. The funding round attracted a mix of strategic investors, including DCI Partners Co., Ltd. as a lead investor, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC who recognize the potential of Rege Nephro in delivering new treatments to patients suffering from their diseases. The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and to prepare for clinical trials in the United States. Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy. Investor Statements DCI Partners Co., Ltd. "We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro." JIC Venture Growth Investments Co., Ltd. "We strongly believe that his advanced drug discovery research based on Professor Osafune's discoveries will provide new therapeutic solutions for intractable renal diseases." Kyoto University Innovation Capital Co., Ltd. "We are delighted that Rege Nephro, which we have supported since before the company was founded, has finally entered the clinical stage. We hope that this funding will accelerate the clinical trials and bring a new therapeutic drug to patients as soon as possible." JAFCO Group Co., Ltd. "We hope that this financing will further accelerate Rege Nephro research and development in iPS drug discovery and provide new treatment options for patients suffering from diseases with limited treatment options." Mitsubishi UFJ Capital Co., Ltd. "Our continued investment reflects our confidence in Rege Nephro's rapid progress and the potential of Professor Osafune's iPS cell technology to significantly impact medical practice." Series B investors About Rege Nephro Co., Ltd. Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases. About RN-014 Tamibarotene, under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function. The Phase II clinical trial began in December 2023. This trial includes a pharmacokinetic (PK) phase and a randomization phase. Various safety measures have been established, including phased patient enrollment, periodic independent safety monitoring, strict criteria for dose reduction and discontinuation of the investigational drug, and criteria for discontinuation of the entire trial. There have been no significant issues at this time. About RN-032 Cell therapy using NPCs for Chronic Kidney Disease (CKD). Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro has been tried implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments. SOURCE Rege Nephro CO., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

STOCKHOLM, June 18, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) is pleased to announce a milestone in radiotherapy technology where RaySearch's RayStation®* was used for the world's first clinical treatment using OXRAY, a new treatment machine from Hitachi. The event took place on June 17 at Narita Memorial Hospital in Toyohashi, Japan. OXRAY represents a pioneering radiotherapy system featuring a Gimbal-mounted beam delivery system. RayStation was used to drive its motion tracking functionality, dual-source CBCT image-guided radiotherapy for precise patient positioning, and dynamic swing arc capabilities. Developed in collaboration with Kyoto University Hospital, the OXRAY system has been seamlessly integrated into RayStation through close collaboration between RaySearch and Hitachi. By joining the innovative capabilities of OXRAY with RayStation's sophisticated planning software, clinicians can achieve unprecedented precision and flexibility in radiation therapy, ensuring optimal patient outcomes. Dr. Yuta Shibamoto, MD of the Meiyo-kai Narita Memorial Hospital group says: "There are so many different cases and challenges we face in daily practice. Having the latest technique will enhance the possibilities of our treatment. We are looking forward to the solution that OXRAY and RayStation brings in." Johan Löf, Founder and CEO of RaySearch, remarked, "The OXRAY system represents a remarkable convergence of advanced radiotherapy technologies. By combining non-coplanar treatments, superior imaging capabilities, a conventional MLC, and real-time tracking, OXRAY delivers a new level of precision and flexibility. The integration with RayStation underscores our commitment to pioneering solutions that enhance cancer treatments." About Narita Memorial Hospital Narita Memorial Hospital, located in Toyohashi City, is part of the Meiyo-kai Hospital group, a distinguished healthcare provider founded in 1951. In 2012, Narita Memorial Hospital established itself as an early adopter of advanced radiotherapy techniques by introducing TomoTherapy. Narita Memorial Hospital achieved another milestone in 2018 by becoming the first healthcare facility in Japan to implement the IBA Proteus One system. About RaySearch RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to more than 1,000 centers in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com. About RayStation RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved. * Subject to regulatory clearance in some markets. For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: +46 (0) 8 510 530 00 [email protected] This information was brought to you by Cision The following files are available for download: SOURCE RaySearch Laboratories